CClinicalTrials.gg
CompletedNCT04740567ECIDUpdated Dec 24, 2025Results posted

Early Cognitive Intervention in Delirium

An interventional study of Cognitive Training and Goal Management Training in Delirium, Cognitive Decline and Dementia, sponsored by Vanderbilt University Medical Center. Completed at 2 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This is a randomized control trial to determine if early cognitive training and rehabilitation improve 4-month cognition in hospitalized older (>=65 years old) delirious patients with and without Alzheimer's disease and related dementias. Enrolled patients will be randomized to receive cognitive intervention versus usual care at a 1:2 allocation ratio. Patients assigned to the cognitive intervention group will receive cognitive training daily during hospitalization and cognitive rehabilitation weekly for 12 weeks after hospital discharge. Patients will be evaluated for global cognition (primary outcome) and secondary outcomes at 4-months.

02

Conditions studied

  • Delirium
  • Cognitive Decline
  • Dementia
03

In context

Delirium

1,057 studies on the registry are indexed under Delirium; 238 are open to participants now.

This study's enrollment of 283 is above the median of 120 across 599 interventional studies indexed under Delirium.

Browse Delirium studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 824 studies on the registry; 164 are open to participants now.

Of its 122 completed or terminated interventional studies of FDA-regulated products, 91 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 65 years or older
  • Admitted through the ED
  • Cognitive training can be initiated within 24 hours of ED presentation
  • Delirious at enrollment

Exclusion criteria

Exclusion Criteria:

  • Comatose
  • Not able to follow simple commands or non-verbal prior to the acute illness (end-stage pre-illness ADRD)
  • Resides in a nursing home
  • Prisoner
  • Receiving hospice care
  • Lives > 100 miles away from the enrolling sites
  • Non-English speaking
  • Previously enrolled
  • Deaf or blind
  • Intravenous drug, crack or cocaine, or methamphetamine use within the past one year, or any condition that, in the investigator's opinion, makes them an unreliable trial patient or unlikely to complete the trial.
  • Psychotic disorder or suicidal gesture requiring hospitalization with the past one year
  • Discharged from the ED
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Cognitive Intervention

    During hospitalization, enrolled patients assigned to the intervention arm will undergo two 20-minute cognitive training sessions daily, 7 days a week. After the patient is discharged from the hospital, cognitive rehabilitation will be administered once a week for 12-weeks at their place of residence. Goal Management Training will be the foundation for cognitive rehabilitation.

    Behavioral: Cognitive Training · Behavioral: Goal Management Training

  • No intervention
    Usual Care

    Enrolled patients will undergo usual care during hospitalization and post-hospital discharge.

Interventions

  • BehavioralCognitive Training

    The cognitive training program regimen and its degree of difficulty will be tailored to the patient's current level of cognitive functioning and interests. Patients will be asked to work through progressively more challenging exercises pertaining to orientation, attention, problem-solving, and memory. These cognitive training exercises will be significantly difficult but when they can be completed easily (\>85% mastery), their difficulty will be increased, and this process will be repeated as appropriate. They will also perform puzzles, games, or cognitive tasks related to their hobbies.

  • BehavioralGoal Management Training

    Goal management training will (1) teach patients compensatory strategies such as "stop" techniques \[e.g., to "stop and think" about consequences of a decision before making it\]; (2) help them to take complex tasks and divide them into manageable subtasks to increase the likelihood of completing the task; and (3) enable them to learn to regain cognitive control when their behavior becomes incompatible with their intended goals. GMT is anchored in "sustained and vigilant attention theory" and it enables patients to actively attend to "higher order" goals critical to functioning. GMT is tailored to the individual needs of the patient. During the initial session, the Cognitive Intervention Specialist will meet with the subject and their family member or caregiver to identify these functional and cognitive deficiencies.

06

What researchers measure

Primary outcomes

  1. Global Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    A neuropsychological battery for global cognition which evaluates immediate and delayed memory, attention, visuospatial construction, and language. Scores range from 40 to 160, with higher scores indicating better cognition.

    Time frame: 4-months

Secondary outcomes

  1. Executive Function as Measured by the Components of the Delis-Kaplan Executive Function System (D-KEFS) Subscales

    The D-KEF's Proverbs, Color Word Interference, and Verbal Fluency Category Switching subscales will measure conceptual flexibility, inhibition, and monitoring, respecitvely, which encompasses the majority of executive function. The average of the three subscales will provide an executive function composite score. Scores range from 1 to 18 with higher values indicating better executive function

    Time frame: 4-months

  2. Functional Status as Measured by Older American Resources and Services Activities of Daily Living Scale

    Characterizes seven basic and seven instrumental activities of daily living. Scores range from 0 to 28 with higher scores indicating better functional status.

    Time frame: 4-months

  3. Quality of Life as Measured by the EQ-5D-5L

    Characterizes quality of life and contains 5-dimensions ("5D") related to everyday living: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It asks patients to rate their current global health status from 0 (worst health you can imagine) to 100 (best health you can imagine). Scores range from -0.573 to 1.000 with higher scores indicating better quality of life.

    Time frame: 4-months

  4. Vital Status (Dead / Alive)

    Death within 4-months will be recorded

    Time frame: 4-months

  5. Nursing Home Placement (Yes / no)

    Nursing home placement within 4-months will be recorded

    Time frame: 4-months

  6. Change in Montreal Cognitive Assessment

    Change in global cognition at 4-months compared to enrollment. The Montreal Cognitive Assessment assesses visuospatial, language, naming, memory, attention, abstraction, and orientation, and ranges from 0 to 30 (perfect cognition). It was collected at enrollment, during the delirium episode, and at 4 months.

    Time frame: 4-months

07

Results

Posted Dec 24, 2025
Limitations and caveats
Limited generalizability since our study was conducted at a quartnerary hospital in the South. Mortality was different between the intervention vs usual care group and overall attrition rate was high for both groups, which may have biased our estimates.

Participant flow

Participant flow — Overall Study
MilestoneCognitive InterventionUsual Care
Started97186
Completed50102
Not completed4784
Withdrew: Death3143
Withdrew: Lost to follow-up211
Withdrew: Patient declined to participate1326
Withdrew: Patient was physically incapable13
Withdrew: Patient's spouse was had prolongued icu stay01

Outcome measures

PrimaryGlobal Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

A neuropsychological battery for global cognition which evaluates immediate and delayed memory, attention, visuospatial construction, and language. Scores range from 40 to 160, with higher scores indicating better cognition.

Time frame:
4-months
Reported as:
Median · score on a scale
Global Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
score on a scaleCognitive InterventionUsual Care
Global Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)67 (49 to 80)67 (52 to 83)
SecondaryExecutive Function as Measured by the Components of the Delis-Kaplan Executive Function System (D-KEFS) Subscales

The D-KEF's Proverbs, Color Word Interference, and Verbal Fluency Category Switching subscales will measure conceptual flexibility, inhibition, and monitoring, respecitvely, which encompasses the majority of executive function. The average of the three subscales will provide an executive function composite score. Scores range from 1 to 18 with higher values indicating better executive function

Time frame:
4-months
Reported as:
Median · score on a scale
Executive Function as Measured by the Components of the Delis-Kaplan Executive Function System (D-KEFS) Subscales
score on a scaleCognitive InterventionUsual Care
Executive Function as Measured by the Components of the Delis-Kaplan Executive Function System (D-KEFS) Subscales5.5 (3 to 8)4.0 (0 to 11)
SecondaryFunctional Status as Measured by Older American Resources and Services Activities of Daily Living Scale

Characterizes seven basic and seven instrumental activities of daily living. Scores range from 0 to 28 with higher scores indicating better functional status.

Time frame:
4-months
Reported as:
Median · score on a scale
Functional Status as Measured by Older American Resources and Services Activities of Daily Living Scale
score on a scaleCognitive InterventionUsual Care
Functional Status as Measured by Older American Resources and Services Activities of Daily Living Scale9 (2 to 16)8 (3 to 13)
SecondaryQuality of Life as Measured by the EQ-5D-5L

Characterizes quality of life and contains 5-dimensions ("5D") related to everyday living: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It asks patients to rate their current global health status from 0 (worst health you can imagine) to 100 (best health you can imagine). Scores range from -0.573 to 1.000 with higher scores indicating better quality of life.

Time frame:
4-months
Reported as:
Median · score on a scale
Quality of Life as Measured by the EQ-5D-5L
score on a scaleCognitive InterventionUsual Care
Quality of Life as Measured by the EQ-5D-5L0.352 (0.096 to 0.727)0.269 (0.096 to 0.465)
SecondaryVital Status (Dead / Alive)

Death within 4-months will be recorded

Time frame:
4-months
Reported as:
Count of participants · Participants
Vital Status (Dead / Alive)
ParticipantsCognitive InterventionUsual Care
Vital Status (Dead / Alive)3143
SecondaryNursing Home Placement (Yes / no)

Nursing home placement within 4-months will be recorded

Time frame:
4-months
Reported as:
Count of participants · Participants
Nursing Home Placement (Yes / no)
ParticipantsCognitive InterventionUsual Care
Nursing Home Placement (Yes / no)22
SecondaryChange in Montreal Cognitive Assessment

Change in global cognition at 4-months compared to enrollment. The Montreal Cognitive Assessment assesses visuospatial, language, naming, memory, attention, abstraction, and orientation, and ranges from 0 to 30 (perfect cognition). It was collected at enrollment, during the delirium episode, and at 4 months.

Time frame:
4-months
Reported as:
Median · score on a scale
Change in Montreal Cognitive Assessment
score on a scaleCognitive InterventionUsual Care
Change in Montreal Cognitive Assessment3.5 (0 to 6.5)4 (0 to 11)

Adverse events

Collected over From enrollment to the 4-month follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitive Intervention31/97 (32%)0/97 (0%)0/97 (0%)
Usual Care43/186 (23.1%)0/186 (0%)0/186 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cognitive InterventionUsual CareTotal
<=18 years000
Between 18 and 65 years000
>=65 years97186283
Age, Continuous
Age, Continuous(years)Cognitive InterventionUsual CareTotal
Median76 (71 to 82)75 (70.3 to 82.0)75 (71 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Cognitive InterventionUsual CareTotal
Female4289131
Male5597152
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitive InterventionUsual CareTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American142741
White81154235
More than one race123
Unknown or Not Reported011
08

Study locations

2 sites
  • Tennessee Valley Healthcare System - Nashville Veteran Affairs Hospital
    Nashville, Tennessee 37027, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37027, United States
09

References and documents

Study documents

  • Study protocol · Feb 4, 2022
  • Statistical analysis plan · Nov 14, 2024
  • Informed consent form · Apr 4, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap, Icf, Analytic code

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04740567
Lead sponsor
Vanderbilt University Medical Center
Collaborators
National Institute on Aging (NIA)
Responsible party
Jin H. Han (Associate Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Feb 5, 2021
Start date
Feb 9, 2021
Primary completion
Nov 14, 2024
Completion
Nov 14, 2024
Results posted
Dec 24, 2025
Last update
Dec 24, 2025

Study contacts

Jin H Han, MD, MSc
principal investigator · Vanderbilt University Medical Center
James C Jackson, PsyD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion